CollPlant Biotechnologies’ (CLGN) Buy Rating Reiterated at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $14.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 416.80% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Price Performance

NASDAQ CLGN opened at $2.71 on Thursday. The stock’s 50-day moving average is $3.50 and its 200-day moving average is $3.96. CollPlant Biotechnologies has a one year low of $2.56 and a one year high of $6.75. The firm has a market cap of $31.03 million, a P/E ratio of -1.76 and a beta of 1.07.

Institutional Investors Weigh In On CollPlant Biotechnologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its holdings in shares of CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after purchasing an additional 4,405 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in CollPlant Biotechnologies in the 4th quarter valued at $38,000. Benjamin Edwards Inc. bought a new stake in CollPlant Biotechnologies during the 3rd quarter worth about $112,000. Finally, AMH Equity Ltd boosted its stake in shares of CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after buying an additional 17,295 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.